Regeneron Secures $125M for Antibody-Helicon Conjugates; EMA Accepts Otarmeni MAA; Maftivimab Shows Lab Activity Against Bundibugyo Ebolavirus (tradingview.com)

• Regeneron receives $125M from Parabilis for Antibody-Helicon Conjugates research.
• EMA accepts Otarmeni MAA under accelerated assessment.
• Maftivimab shows in vitro activity against Bundibugyo ebolavirus, with WHO evaluation ongoing.

"Regeneron (REGN) announced a $125M research deal with Parabilis to develop Antibody-Helicon Conjugates for five targets, including $50M upfront and $75M equity, with up to $2.2B milestones. The European Medicines Agency accepted the Marketing Authorisation Application for Otarmeni (lunsotogene parvec) under accelerated assessment for a non-Ebola indication. Separately, Regeneron reported that its monoclonal antibody maftivimab demonstrates in vitro activity against Bundibugyo ebolavirus and is under WHO evaluation for potential supply and delivery."